STEPHANIE ELLERBE: Open Payments
NPI 1962834499 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,378 in 179 payments from 13 companies in 2025. Trend: 2023 $1,317 · 2024 $733 · 2025 $3,378
Food & beverage: $3,378
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 24 | $871 |
| E.R. Squibb & Sons, L.L.C. | 26 | $437 |
| Alkermes, Inc. | 17 | $346 |
| Teva Pharmaceuticals USA, Inc. | 22 | $319 |
| ABBVIE INC. | 21 | $282 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $265 |
| Otsuka America Pharmaceutical, Inc. | 20 | $248 |
| Vanda Pharmaceuticals Inc. | 7 | $153 |
| Lundbeck LLC | 6 | $118 |
| Janssen Pharmaceuticals, Inc | 6 | $113 |
Products named: INGREZZA, COBENFY, ARISTADA, REXULTI, VRAYLAR, CAPLYTA, AUSTEDO XR, FANAPT.
Industry payments across FL — which companies pay providers there.
